Search Results
Feb 12, 2026, 16:02 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc. and Certain Officers - INO
for Inovio's CELLECTRA device was deficient; (ii) accordingly, Inovio was unlikely to submit the INO-3107 BLA to the FDA by the second half of 2024; (iii) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (iv) accordingly, INO-3107's overall regulatory
More news about: Pomerantz LLP
Feb 12, 2026, 16:02 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Beyond Meat, Inc. and Certain Officers - BYND
foregoing was likely to impair Beyond Meat's ability to timely file its periodic filings with the U.S. Securities and Exchange Commission ("SEC"); and (iii) as a result, Defendants' public statements were materially false and misleading at all relevant times.The complaint alleges that
More news about: Pomerantz LLP
Feb 12, 2026, 16:02 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Plug Power Inc. and Certain Officers - PLUG
facilities necessary to receive those funds; (ii) as such, Plug Power was likely to pivot toward more modest projects with less commercial upside; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.On October 7, 2025, Plug Power issued
More news about: Pomerantz LLP
Feb 12, 2026, 16:02 ET Pomerantz Law Firm Announces the Filing of a Class Action Against CoreWeave, Inc. and Certain Officers - CRWV
that CoreWeave's reliance on a single third-party data center supplier presented for CoreWeave's ability to meet customer demand for its services; (iii) the foregoing was reasonably likely to have a material negative impact on the Company's revenue; (iv) as a result, the Company's public statements were
More news about: Pomerantz LLP
Feb 12, 2026, 16:01 ET Wynn Resorts, Limited Reports Fourth Quarter and Year End 2025 Results
attributable to Wynn Resorts, Limited to adjusted net income attributable to Wynn Resorts, Limited, (ii) operating income to Adjusted Property EBITDAR, and (iii) net income attributable to Wynn Resorts, Limited to Adjusted Property EBITDAR.
More news about: Wynn Resorts, Limited
Feb 12, 2026, 15:30 ET LA COMMISSION EUROPEENNE APPROUVE UPLIZNA® D'AMGEN DANS LE CADRE DU TRAITEMENT DE LA MYASTHÉNIE GRAVE GÉNÉRALISÉE
patients MuSK+.5Les critères d'éligibilité lors de la sélection et de la randomisation étaient les suivants : une classification II, III ou IV de la maladie selon la Myasthenia Gravis Foundation of America (MGFA), un score MG-ADL compris entre 6 et 10, dont plus de 50 % attribués à des
More news about: Amgen
Feb 12, 2026, 15:15 ET La Comisión Europea aprueba UPLIZNA® de Amgen para la miastenia gravis generalizada
de elegibilidad en la selección y aleatorización incluyeron una clasificación de la Myasthenia Gravis Foundation of America (MGFA) de enfermedad II, III o IV, una puntuación MG-ADL entre 6 y 10 con más del 50 % de esta puntuación atribuida a elementos no oculares, o una puntuación MG-ADL de al menos 11,
More news about: Amgen
Feb 12, 2026, 15:13 ET The Inner Circle acknowledges David Reynolds Thrasher, MD as a Pinnacle Professional Member Inner Circle of Excellence
Dr. Thrasher has been recognized with numerous awards, including the W. Kelly Mosley Environment Award from Auburn University, the Battle S. Searcy III Memorial Award for Psychiatry, the International Quality of Life Award by Auburn University, and the Ethics in Business Award. In 2021, he was honored
More news about: The Inner Circle
Feb 12, 2026, 15:00 ET Investors in Ultragenyx Pharmaceutical Inc. Should Contact The Gross Law Firm Before April 6, 2026 to Discuss Your Rights - RARE
decrease in annualized fracture rates or otherwise the Phase III Orbit and Cosmic studies were much less likely to be able to demonstrate such a link than management claimed. On December 29, 2025, Ultragenyx announced that both its Phase III Orbit and Cosmic Studies had not "achieved statistical significance
More news about: The Gross Law Firm
Feb 12, 2026, 15:00 ET Contact The Gross Law Firm by March 13, 2026 Deadline to Join Class Action Against CoreWeave, Inc.(CRWV)
that CoreWeave's reliance on a single third-party data center supplier presented for CoreWeave's ability to meet customer demand for its services; (iii) the foregoing was reasonably likely to have a material negative impact on the Company's revenue; (iv) as a result, the Company's public statements were
More news about: The Gross Law Firm
Feb 12, 2026, 15:00 ET Shareholders that lost money on Beyond Meat, Inc.(BYND) should contact The Gross Law Firm about pending Class Action - BYND
material, non-cash impairment charge; (ii) the foregoing was likely to impair Beyond Meat's ability to timely file its periodic filings with the SEC; and (iii) as a result, defendants' public statements were materially false and misleading at all relevant times.DEADLINE: March 24, 2026 Shareholders
More news about: The Gross Law Firm
Feb 12, 2026, 15:00 ET SLM LAWSUIT ALERT: The Gross Law Firm Notifies SLM Corporation Investors of a Class Action Lawsuit and Upcoming Deadline
loss mitigation and/or loan modification programs, as well as the overall stability of the Company's private education loan delinquency rates; and (iii) as a result, defendants' public statements made a materially false and misleading impression regarding SLM's business, operations, and prospects at
More news about: The Gross Law Firm
Feb 12, 2026, 15:00 ET The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 3, 2026 in Plug Power Inc. Lawsuit - PLUG
facilities necessary to receive those funds; (ii) as such, Plug Power was likely to pivot toward more modest projects with less commercial upside; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.DEADLINE: April 3, 2026 Shareholders
More news about: The Gross Law Firm
Feb 12, 2026, 12:37 ET RARE Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against Ultragenyx Pharmaceutical Inc. (RARE)
Ultragenyx's Phase III Orbit study would fail to achieve a statistically significant reduction in annualized fracture rate ("AFR"), such that the second interim analysis could be performed and presented to the investing public; (2) in truth, Ultragenyx's optimism in the Phase III Orbit study's results
More news about: Kessler Topaz Meltzer & Check, LLP
Feb 12, 2026, 11:00 ET PITTCO PROMOTES CORIE RIVERS TO CHIEF ACCOUNTING OFFICER
her continued leadership in this role."ABOUT PITTCO MANAGEMENT, LLCPittco is the single-family office for Joseph R. "Pitt" Hyde III, founder of AutoZone, and his wife, Barbara. Pittco was established over 30 years ago, and provides investment, accounting, tax, and financial services
More news about: Pittco Management, LLC
Feb 12, 2026, 10:07 ET Contango Webinar Scheduled for Thursday February 12, 2026
project from the underlying owner, Cook Inlet Region, Inc.; (ii) a lease on the Lucky Shot project from the underlying owner, Alaska Hardrock Inc.; (iii) a 100% interests held through it wholly owned subsidiary Contango Minerals Alaska, LLC in approximately 145,280 acres of State of Alaska mining claims;
More news about: Contango Ore
Feb 12, 2026, 10:05 ET Contango Ore Closes $50 Million Underwritten Offering of Common Stock and Pre-funded Warrants
project from the underlying owner, Cook Inlet Region, Inc.; (ii) a lease on the Lucky Shot project from the underlying owner, Alaska Hardrock Inc.; (iii) a 100% interests held through it wholly owned subsidiary Contango Minerals Alaska, LLC in approximately 145,280 acres of State of Alaska mining claims;
More news about: Contango Ore
Feb 12, 2026, 09:00 ET Sanyou Biopharmaceuticals Lang Guojun: Making Innovative Biologics R&D Easier for Clients Worldwide
projects, signed over 60 collaborations, of which 10 have completed IND submissions, 8 are clinically active projects, and 3 have progressed to Phase III or confirmatory clinical stages.The MarathonLooking back at Sanyou Biopharmaceuticals' journey, several core themes have consistently
More news about: Sanyou Bio
Feb 12, 2026, 09:00 ET EUROPEAN COMMISSION APPROVES AMGEN'S UPLIZNA® FOR GENERALIZED MYASTHENIA GRAVIS
MuSK+.5Eligibility criteria at screening and randomization included a Myasthenia Gravis Foundation of America (MGFA) classification of II, III or IV disease, MG-ADL score between 6 and 10 with greater than 50% of this score attributed to non-ocular items, or an MG-ADL score of at least 11, and
More news about: Amgen
Feb 12, 2026, 08:30 ET YY Group's Director of Southeast Asia Ken Teng Receives HAPA Hospitality Service Entrepreneur Award
forward-looking statement. These factors include, but are not limited to, (i) growth of the hospitality market (ii) capital and credit market volatility, (iii) local and global economic conditions, (iv) our anticipated growth strategies, (v) governmental approvals and regulations, and (vi) our future business
More news about: YY Group Holding Limited
Feb 12, 2026, 08:19 ET TNL Mediagene Announces GIZMART's Debut Project "Keychron Nape Pro" Wins Tom's Hardware's "Best of CES 2026 - Best Mouse" Award
new product categories. Recently launched projects include Meizu's StarV Air2, an augmented reality (AR) smart glasses device, and Belfida's MAGIC MIC III, a wireless headset-style microphone system.About GIZMARTGIZMART is a media-commerce platform operated by Gizmodo Japan, offering
More news about: TNL Mediagene
Feb 12, 2026, 08:01 ET New "Hypertension Bites" Campaign Urges Adults to Prioritize Blood Pressure Control
https://www.cdc.gov/high-blood-pressure/about/index.htmliii Centers for Disease Control and Prevention. High Blood Pressure Priorities.
More news about: Hypertension Control Alliance
Feb 12, 2026, 07:37 ET ARTDAI Launches Collection Management Platform for Family Offices
took everything we learned building data infrastructure for enterprise clients and delivered that capability directly to family offices," John Forlines III, Executive Chairman added. "This is the same technology managing billions in art exposure for major insurers and lenders. Now, it's available to the
More news about: ARTDAI
Feb 12, 2026, 07:30 ET Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
multiple myeloma after at least one prior therapy; (ii) in combination with dexamethasone in adult patients with heavily pre-treated multiple myeloma; and (iii) under accelerated approval in adult patients with diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from follicular lymphoma, after at
More news about: Karyopharm Therapeutics Inc.
Feb 12, 2026, 07:17 ET i-80 Gold Secures Financing Package of up to $500 Million to Advance Development Plan
Loan with Orion Resource Partners (across various funds) with the exception of a Silver Purchase and Sale Agreement held by Orion Mine Finance Fund III (HG) Ltd. Additionally, Convertible Debentures amounting to approximately $86 million will be retired from the proceeds of the Financing Package. Convertible
More news about: i-80 Gold Corp